| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1760 | 2020 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 447 | 2021 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 269 | 2021 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ... Cell research 29 (10), 846-861, 2019 | 201 | 2019 |
| CD73–adenosine: a next-generation target in immuno-oncology D Allard, B Allard, PO Gaudreau, P Chrobak, J Stagg Immunotherapy 8 (2), 145-163, 2016 | 146 | 2016 |
| The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements: supplementary issue: biomarkers and their essential role in the … PO Gaudreau, J Stagg, D Soulières, F Saad Biomarkers in cancer 8, BIC. S31802, 2016 | 125 | 2016 |
| Immunotherapy comes of age in lung cancer P Khanna, N Blais, PO Gaudreau, L Corrales-Rodriguez Clinical lung cancer 18 (1), 13-22, 2017 | 102 | 2017 |
| Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis G Gobbi, PO Gaudreau, N Leblanc Journal of Clinical Psychopharmacology 26 (5), 467-473, 2006 | 76 | 2006 |
| The impact of intratumoral and gastrointestinal microbiota on systemic cancer therapy AP Cogdill, PO Gaudreau, R Arora, V Gopalakrishnan, JA Wargo Trends in immunology 39 (11), 900-920, 2018 | 73 | 2018 |
| Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer L Federico, DJ McGrail, SE Bentebibel, C Haymaker, A Ravelli, MA Forget, ... Annals of Oncology 33 (1), 42-56, 2022 | 69 | 2022 |
| Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC PO Gaudreau, MV Negrao, KG Mitchell, A Reuben, EM Corsini, J Li, ... Journal of Thoracic Oncology 16 (1), 127-139, 2021 | 65 | 2021 |
| Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers DH Peng, BL Rodriguez, L Diao, PO Gaudreau, A Padhye, JM Konen, ... Nature communications 12 (1), 2606, 2021 | 52 | 2021 |
| CD73-adenosine reduces immune responses and survival in ovarian cancer patients PO Gaudreau, B Allard, M Turcotte, J Stagg Oncoimmunology 5 (5), e1127496, 2016 | 45 | 2016 |
| Immune checkpoint blockade across the cancer care continuum BA Helmink, PO Gaudreau, JA Wargo Immunity 48 (6), 1077-1080, 2018 | 38 | 2018 |
| ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results V Anagnostou, C Ho, G Nicholas, RA Juergens, A Sacher, AS Fung, ... Nature medicine 29 (10), 2559-2569, 2023 | 26 | 2023 |
| WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors PO Gaudreau, S Clairefond, CA Class, PL Boulay, P Chrobak, B Allard, ... Oncoimmunology 8 (5), e1581545, 2019 | 25 | 2019 |
| iRECIST and atypical patterns of response to immuno-oncology drugs JL Ramon-Patino, S Schmid, S Lau, L Seymour, PO Gaudreau, JJN Li, ... Journal for Immunotherapy of Cancer 10 (6), 2022 | 15 | 2022 |
| Phase I/II trial of immunotherapy with durvalumab and tremelimumab with continuous or intermittent MEK inhibitor selumetinib in NSCLC: early trial report PO Gaudreau, JJ Lee, JV Heymach, DL Gibbons Clinical lung cancer 21 (4), 384-388, 2020 | 15 | 2020 |
| Brief report: canadian cancer trials group IND. 227: A phase 2 randomized study of pembrolizumab in patients with advanced Malignant pleural mesothelioma (NCT02784171) MC Piccirillo, Q Chu, P Bradbury, W Tu, CH Coschi, F Grosso, M Florescu, ... Journal of Thoracic Oncology 18 (6), 813-819, 2023 | 11 | 2023 |
| Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma MG White, R Szczepaniak Sloane, RG Witt, A Reuben, PO Gaudreau, ... Oncoimmunology 10 (1), 1992880, 2021 | 8 | 2021 |
